Antiparasitic activity of risedronate in a murine model of acute Chagas' disease

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 286-290

  Garzoni, Luciana R ^a   Waghabi, Mariana C ^a   Baptista, Marcos M ^a   De Castro, Solange L ^a   Meirelles, Maria De Nazareth L ^a   Britto, Constança C ^a   Docampo, Roberto ^b   Oldfield, Eric ^b   Urbina, Julio A ^c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Amastigote; Mouse model; Risedronate; Trypanocidal

Indexed keywords

RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE; SURVIVAL RATE; TREATMENT WITHDRAWAL; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; WEIGHT GAIN;

EID: 1442287477     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.07.019     Document Type: Article

References (25)

1. World Health Organization. Control of Chagas' disease. Technical reports series 2002;905:1-109.
2. Pinto Dias JC, Epidemiologia. In: Brener Z, Andrade Z, Barral-Netto C, editors. Trypanosoma cruzi e doença de Chagas. 2nd ed. Guanabara Koogan: Rio de Janeiro; 1999. p. 48-74.
3. Urbina J.A. Specific treatment of Chagas' disease: current status and new developments. Curr. Opin. Infect. Dis. 14:2001;733-741.
4. Urbina J.A. Chemotherapy of Chagas' disease. Curr. Pharmaceut. Design. 8:2002;287-295.
5. Docampo R. Recent developments in the chemotherapy of Chagas' disease. Curr. Pharmaceut. Design. 7:2001;1157-1164.
6. Coura J.R., de Castro S.L. A critical review on Chagas disease chemotherapy. Memórias do Instituto Oswaldo Cruz. 97:2002;3-24.
7. Urbina J.A., Moreno B., Vierkotter S., Oldfield E., Payares G., Sanoja C.et al. Trypanosoma cruzi contains major pyrophosphate stores and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J. Biol. Chem. 274:1999;33609-33615.
8. 2+ storage compartment in Trypanosomatids and Apicomplexan parasites. Parasitol. Today. 15:1999;443-448.
9. Docampo R., Moreno S.N.J. The acidocalcisome. Mol. Biochem. Parasitol. 33:2001;151-159.
10. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289:2000;1508-1514.
11. Martin M.B., Grimley J.S., Lewis J.C., Heath III H.T., Bailey B.N., Kendrick H.et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44:2001;909-916.
12. Montalvetti A., Bailey B.N., Martin M.B., Severin G.W., Oldfield E., Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. 276:2001;33930-33937.
13. Garzoni L.R., Caldera A., Meirelles M.N.L. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Ag. 23:2004;273-285.
14. Yardley V., Khan A., Martin M.B., Slifer T.R., Araujo F.G., Moreno S.N.J.et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Ag. Chemother. 46:2002;929-931.
15. Rodriguez N., Bailey B.N., Martin M.B., Oldfield E., Urbina J.A., Docampo R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. 86:2002;138-140.
16. Docampo R., Moreno S.N.J. Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites. Curr. Drug Targets: Infect. Disord. 1:2001;51-61.
17. Grove J.E., Brown R.J., Watts D.J. The intracellular target of the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J. Bone Miner. Res. 15:2000;971-981.
18. Bergstrom J.D., Bostedor R.G., Massarachia P.J., Reszka A.A., Rodan G.A. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373:2000;231-241.
19. Reszka A.A., Halasy-Nagy J., Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59:2001;193-202.
20. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D.et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Therapeut. 296:2001;235-242.
21. Silva L.H.P., Nussenszweig V. Sobre uma cepa de Trypanosoma cruzi virulenta para o camundongo branco. Folia Clin. Biol. 20:1953;191-207.
22. Hudson L., Grover F., Gutteridge W.E., Klein R.A., Peters W., Neal R.A. et al. Suggested guidelines for work with live Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 77:1983;416-419.
23. Urbina J.A., Payares G., Contreras L.M., Liendo A., Sanoja C., Molina J.et al. Cure of short- and long-term experimental Chagas' disease using D0870. Science. 273:1996;969-971.
24. Urbina J.A., Payares G., Contreras L.M.et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Ag. Chemother. 42:1998;1771-1777.
25. Wincker P., Britto C., Pereira J.B., Cardoso M.A., Oelemann W., Morel C.M. Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area. Am. J. Trop. Med. Hyg. 51:1994;771-777.